



## URGENT FIELD SAFETY NOTICE

Product name: Actim® Partus Test

Date: September 20<sup>th</sup>, 2024

| Product name (catalogue number) | Lot numbers |
|---------------------------------|-------------|
| Actim® Partus Test (31931ETAL)  | 2005341     |

### Dear Receiver,

The purpose of this letter is to inform you of a withdrawal of the Actim Partus lot mentioned above.

### Description of the problem

Our stability testing has shown that the results of Actim Partus — lot 2005341— do not fulfill the acceptance criteria. A risk for non-specific binding has been identified in this lot. The non-specific binding could cause the appearance of a very faint test line in the result window, indicating a false positive result. True positive results are still obtained from samples with elevated concentrations of phIGFBP-1.

**To mitigate the risk of false positive patient results, we have decided to withdraw the kit lot 2005341 from the market.** As the lot have fulfilled the specifications at earlier testing time points, there is no need for patient follow-up. The root cause analysis is under investigation.

Actim Partus is intended to help assess the risk of preterm or imminent delivery. Treatment decisions during pregnancy must be based on the entire clinical picture of the patient, and not on a test result alone. A false positive result without taking into account the other clinical findings could mislead the clinical decision-making and may cause a risk for overtreatment of the patient.

#### Actim – a part of Medix Biochemica

Headquarters: Klovipellontie 3, FI-02180 Espoo, Finland

Manufacturing site: Noljakantie 13, FI-80130 Joensuu, Finland

[actim@actimtest.com](mailto:actim@actimtest.com)

[www.actimtest.com](http://www.actimtest.com)

VAT reg.no. FI29540422

**Actions required from the receiver:**

1. Confirm via email that you have received this information.
2. Inform all your customers who have received the Actim Partus lot mentioned above about this withdrawal by providing the Field Safety Notice letter. Please use the separately attached word file as a template.
3. Advise your customers to discard the Actim Partus kits that have been withdrawn due to this notification.
4. Assess the number of kits delivered to your customer. Please inform us about your kits in the form "Distributor verification form".
5. Assess the number of kits in your storage. Please inform us about your kits in the form "Distributor verification form"
6. Fill out the "Distributor verification form" and email it to Actim [support@actimtest.com](mailto:support@actimtest.com) by 20.11.2024 the latest.

**Transmission of this Field Safety Notice**

This notice needs to be shared with all the stakeholders within your organization who need to be aware of it.

The undersigned confirms that this notice is sent to the appropriate National Competent Authorities.

Please accept our sincere apology for any inconvenience this matter might have caused.

Should you have any questions or concerns, please contact the undersigned.

Yours sincerely,



Tiina Vilkkinen

Head of QA and RA

**Contact reference person:**

Tiina Vilkkinen

Head of QA and RA

Actim Oy

Klovinpellontie 3, FI-02180 Espoo, Finland

Tel. +358 9 547 68 138

Mobile +358 40 7464744

Email: [tiina.vilkkinen@actimtest.com](mailto:tiina.vilkkinen@actimtest.com)

[www.actimtest.com](http://www.actimtest.com)



## DISTRIBUTOR VERIFICATION FORM

### PRODUCT FIELD SAFETY NOTICE

We acknowledge receipt of the Actim Product Field Safety Notice dated September 20<sup>th</sup>, 2024 for the below product:

Product name: Actim® Partus Test

Catalogue number: 31931ETAL

Lot number: 2005341

Yes ☐

Date \_\_\_\_\_

We have advised our customer to discard the kits that have expired due to this notification.

Yes ☐

No ☐

Date \_\_\_\_\_

| Kit lot | Kits in distributor's storage | Kits in customers' storage |
|---------|-------------------------------|----------------------------|
|         |                               |                            |
|         |                               |                            |
|         |                               |                            |

#### Actim – a part of Medix Biochemica

Headquarters: Klovipellontie 3, FI-02180 Espoo, Finland  
Manufacturing site: Noljaantie 13, FI-80130 Joensuu, Finland

actim@actimtest.com  
www.actimtest.com

VAT reg.no. FI29540422



Authorised signature:

Date:

Print name:

Title:

Company name:

Address:

City:

State:

Postal code:

Country:

Phone:

Email:

**Actim – a part of Medix Biochemica**

Headquarters: Klovipellontie 3, FI-02180 Espoo, Finland

Manufacturing site: Nolkakantie 13, FI-80130 Joensuu, Finland

actim@actimtest.com

www.actimtest.com

VAT reg.no. FI29540422